Alpha Healthcare Acquisition Corp. Iii Announces Non-Binding Letter Of Intent To Acquire A Commercial Stage Regenerative Medicine Company Conditioned Upon Closing Of Carmell Business Combination
Jun 27, 2023•about 2 years ago
Acquiring Company
Alpha Healthcare Acquisition III
Acquired Company
Stage Regenerative Medicine
Description
Alpha Healthcare Acquisition Corp. III (Nasdaq: ALPA) (“ALPA”), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the execution of a non-binding letter of intent (the “LOI”) to acquire a commercial stage regenerative medicine company (the “Target”) conditioned upon the closing of ALPA’s initial business combination with Carmell Therapeutics Corporation, a Phase 2 stage regenerative medicine platform company developing allogeneic plasma-based biomaterials for active soft tissue repair, aesthetics and orthopedic indications (“Carmell”).
DealWatch™ Score
66
High M&A Activity
M&A Opportunity Analysis
Get personalized insights on M&A opportunities
M&A Insights
Based on deal dataIntegration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed